International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

The human gut is home to trillions of microorganisms, collectively known as the gut microbiota, which play a pivotal role in maintaining overall health. These microorganisms are involved in critical processes such as digestion, immune regulation, and protection against pathogens. However, when the delicate balance of the gut microbiota is disrupted a condition known as dysbiosis it can have far-reaching consequences for health, including the development of colorectal cancer (CRC).

Colorectal cancer is one of the most common and deadly cancers worldwide, with its incidence influenced by genetic, environmental, and lifestyle factors. Emerging research highlights the gut-immunity-cancer axis as a key player in CRC development, where dysbiosis contributes to chronic inflammation, immune dysregulation, and tumorigenesis. This article explores the intricate relationship between gut microbiota, immunity, and colorectal cancer, shedding light on how dysbiosis drives cancer progression and the potential for therapeutic interventions [1].

Description

The gut microbiota and its role in health

The gut microbiota is a diverse ecosystem comprising bacteria, viruses, fungi, and archaea. In a healthy state, this microbial community exists in harmony, supporting various physiological functions. Beneficial bacteria such as Lactobacillus and Bifidobacterium produce short-chain fatty acids (SCFAs) like butyrate, which have anti-inflammatory and anti-carcinogenic properties. These metabolites help maintain the integrity of the intestinal barrier, regulate immune responses, and promote apoptosis in abnormal cells [2].

The gut microbiota also interacts with the immune system, training it to distinguish between harmful and harmless entities. This interaction is crucial for preventing inappropriate immune responses that could lead to chronic inflammation or autoimmune diseases [3].

Dysbiosis and its impact on colorectal cancer

Dysbiosis refers to an imbalance in the composition, diversity, or function of the gut microbiota. Factors such as poor diet, antibiotic use, stress, and infections can disrupt the microbial equilibrium, leading to an overgrowth of pathogenic bacteria and a decline in beneficial species. This imbalance has been implicated in the initiation and progression of colorectal cancer through several mechanisms:

Chronic inflammation: Dysbiosis can trigger a pro-inflammatory environment in the gut. Pathogenic bacteria such as Fusobacterium nucleatum and Escherichia coli produce virulence factors that activate inflammatory pathways, including NF-κB and STAT3. Chronic inflammation damages the intestinal epithelium, creating a fertile ground for tumorigenesis [4].

Genotoxic effects: Certain bacteria associated with dysbiosis produce genotoxins that directly damage DNA. For example, E. coli strains harboring the pks pathogenicity island produce colibactin, a genotoxin that induces DNA double-strand breaks, contributing to mutations and cancer development.

Immune dysregulation: Dysbiosis disrupts the balance between pro-inflammatory and anti-inflammatory immune responses. A shift toward a pro-inflammatory state can impair immune surveillance, allowing cancer cells to evade detection and grow unchecked [5].

Metabolic alterations: Dysbiosis affects the production of metabolites such as SCFAs, bile acids, and polyamines. A reduction in SCFAs like butyrate deprives the colon of their protective effects, while altered bile acid metabolism can promote carcinogenesis.

Barrier dysfunction: Dysbiosis compromises the integrity of the intestinal barrier, allowing microbial products such as lipopolysaccharides (LPS) to enter the bloodstream. This systemic exposure to microbial antigens can further exacerbate inflammation and immune dysregulation.

The gut-immunity-cancer axis

The gut-immunity-cancer axis represents the dynamic interplay between the gut microbiota, the immune system, and cancer development. In the context of colorectal cancer, dysbiosis acts as a catalyst for this axis, driving a cascade of events that culminate in tumorigenesis.

Microbial influence on immune responses: The gut microbiota modulates both innate and adaptive immune responses. Beneficial microbes promote the differentiation of regulatory T cells (Tregs) and the production of anti-inflammatory cytokines like IL-10. Dysbiosis, on the other hand, skews the immune response toward a pro-inflammatory phenotype, characterized by increased levels of IL-6, TNF-α, and IL-17 [6].

Tumor microenvironment: Dysbiosis contributes to the formation of a tumor-promoting microenvironment. Pathogenic bacteria and their metabolites can recruit myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), which suppress anti-tumor immunity and support cancer progression.

Therapeutic implications: Understanding the gut-immunity-cancer axis opens new avenues for therapeutic interventions. Strategies such as probiotics, prebiotics, and fecal microbiota transplantation (FMT) aim to restore microbial balance and enhance anti-tumor immunity. Additionally, targeting specific microbial metabolites or pathways offers a promising approach to complement existing cancer therapies [7].

Challenges and future directions

While the role of dysbiosis in colorectal cancer is well-established, several challenges remain in translating this knowledge into clinical practice. Identifying specific microbial signatures associated with CRC risk and progression is crucial for developing diagnostic biomarkers and personalized interventions. Moreover, the complexity and variability of the gut microbiota across individuals necessitate a tailored approach to microbiome-based therapies. Future research should focus on elucidating the causal relationships between dysbiosis and CRC, exploring the impact of diet and lifestyle on the gut microbiota, and investigating the potential of microbiome-targeted therapies in combination with immunotherapy and chemotherapy.

Conclusion

The gut-immunity-cancer axis underscores the profound influence of the gut microbiota on colorectal cancer development. Dysbiosis disrupts the delicate balance of microbial and immune interactions, driving chronic inflammation, immune dysregulation, and tumorigenesis. Understanding this intricate relationship offers valuable insights into the mechanisms underlying CRC and highlights the potential for microbiome-based interventions in cancer prevention and treatment. As research in this field advances, integrating microbiome-targeted strategies into clinical practice holds the promise of transforming colorectal cancer management. By restoring microbial balance and harnessing the power of the gut-immunity-cancer axis, we can pave the way for more effective and personalized approaches to combating this devastating disease.

Acknowledgement

None

Conflict of Interest

None

References

1. Poli A, Finore I, Romano I, Gioiello A, Lama L, et al. (2017) Microbial Diversity in Extreme Marine Habitats and Their Biomolecules. Microorganisms 5: 25.
2. Firn RD, Jones CG (2000) The evolution of secondary metabolism-a unifying model. Mol Microbiol 37: 989-994.
3. Giordano D, Coppola D, Russo R, Denaro R, Giuliano L, et al. (2015) Marine Microbial Secondary Metabolites: Pathways, Evolution and Physiological Roles. Adv Microb Physiol 66: 357-428.
4. Carneiro VC, Lyko F (2020) Rapid Epigenetic Adaptation in Animals and Its Role in Invasiveness. Integr Comp Biol 60: 267-274.
5. Mirbahai L, Chipman JK (2014) Epigenetic memory of environmental organisms: A reflection of lifetime stressor exposures. Mutat Res Genet Toxicol Environ Mutagen 65: 10-17.
6. Jeremias G, Barbosa J, Marques SM, Asselman J, Goncalves FJM, et al. (2018) Synthesizing the role of epigenetics in the response and adaptation of species to climate change in freshwater ecosystems. Mol Ecol 27: 2790-2806.
7. Seca AML, Pinto D (2018) Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application. Int J Mol Sci 19:263.